Nature Medicine, Published online: 18 January 2021; doi:10.1038/s41591-020-01189-2
Exploratory analyses from the phase 2 randomized SAFIR02-IMMUNO trial identify biomarkers associated with improved outcomes to durvalumab as compared to maintenance chemotherapy in patients with triple-negative breast cancer.
Source: Nature Medicine